4/4
08:04 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/3
08:11 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.
3/18
02:59 pm
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
3/14
04:21 pm
lrmr
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development [Yahoo! Finance]
Low
Report
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development [Yahoo! Finance]
3/14
04:05 pm
lrmr
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Low
Report
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
3/11
04:27 pm
lrmr
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia [Yahoo! Finance]
Medium
Report
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia [Yahoo! Finance]
3/11
04:05 pm
lrmr
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
Low
Report
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
3/6
04:10 pm
lrmr
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
Low
Report
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
3/6
04:05 pm
lrmr
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Low
Report
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
3/6
11:34 am
lrmr
Top 10 best performing biotech stocks of 2024 so far [Seeking Alpha]
Low
Report
Top 10 best performing biotech stocks of 2024 so far [Seeking Alpha]
2/23
06:33 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.
2/16
04:20 pm
lrmr
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Medium
Report
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2/14
06:15 am
lrmr
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
High
Report
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
2/13
04:26 pm
lrmr
Larimar Therapeutics Announces Proposed Underwritten Public Offering [Yahoo! Finance]
High
Report
Larimar Therapeutics Announces Proposed Underwritten Public Offering [Yahoo! Finance]
2/13
04:18 pm
lrmr
Larimar Therapeutics Announces Proposed Underwritten Public Offering
High
Report
Larimar Therapeutics Announces Proposed Underwritten Public Offering
2/13
10:58 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $4.50 to $10.00. They now have a "buy" rating on the stock.
High
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $4.50 to $10.00. They now have a "buy" rating on the stock.
2/13
09:24 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at JMP Securities from $17.00 to $25.00. They now have a "market outperform" rating on the stock.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at JMP Securities from $17.00 to $25.00. They now have a "market outperform" rating on the stock.
2/12
07:13 am
lrmr
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia [Yahoo! Finance]
High
Report
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia [Yahoo! Finance]
2/12
07:00 am
lrmr
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
Medium
Report
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia